Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365480 · ClinicalTrials.gov registry record · Phase 1
Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02365480: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02365480 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02365480, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This randomized, pilot phase I trial studies the side effects of berberine chloride in treating patients with ulcerative colitis and who are in remission (a decrease in or disappearance of signs and symptoms of cancer) to reduce the risk of colorectal cancer. Patients with ulcerative colitis are at increased risk for colorectal cancer. Chemoprevention is the use of drugs, such as berberine chloride, to keep a disease/condition from forming or coming back. The use of berberine chloride may keep colorectal cancer from forming in patients with ulcerative colitis.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Placebo Administration
- DRUG Berberine Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-06-16 |
| Est. Completion | 2019-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365480
The ClinicalTrials.gov registry entry for NCT02365480 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02365480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02365480 about?
NCT02365480 is a clinical study titled "Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission". This randomized, pilot phase I trial studies the side effects of berberine chloride in treating patients with ulcerative colitis and who are in remission (a decrease in or disappearance of signs and symptoms of cancer) to reduce the risk of colorectal cancer. Patients with ulcerative colitis are at ...
What is the current status of trial NCT02365480?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-06-16. Estimated completion is 2019-12-13.
What interventions are being tested in trial NCT02365480?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Placebo Administration (OTHER), Berberine Chloride (DRUG).
Who is sponsoring clinical trial NCT02365480?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.